InfuSystems HoldingsINFU +0.77%88 ROE % is 7.01% as of Mar. 2026, which is 184% above its 10-year median of 2.47. GuruFocus rates INFU with a GF Score™ of 88/100 and a GF Value™ of $9.44 (Fairly Valued). The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, InfuSystems Holdings ranks better than 83.48% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InfuSystems Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
InfuSystems Holdings (INFU) has a ROE % of 7.01% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on InfuSystems Holdings and its competitors. This is 184% above median its historical median of 2.47. According to the industry distribution chart, InfuSystems Holdings ranks #132 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 16.5%.
Is InfuSystems Holdings' ROE % too high?
InfuSystems Holdings' current ROE % of 7.01% is 184% above median its 10-year median of 2.47. The Medical Devices & Instruments industry median ROE % is 2.42. InfuSystems Holdings' value of 7.01% is 189.7% above this industry median. Based on the distribution chart, InfuSystems Holdings ranks #132 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InfuSystems Holdings has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' ROE % compare to TANAF and INGN?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #132 out of 799 companies for ROE %. This places InfuSystems Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. InfuSystems Holdings' value of 7.01% is 189.7% above this benchmark. While the company's 10-year median is 2.47 vs. the industry median of 2.42, InfuSystems Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InfuSystems Holdings's current ROE % of 7.01% is 189.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on InfuSystems Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current ROE % is 7.01%, which is 184% above median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Fairly Valued. The stock's GF Value™ is $9.44, compared to a current price of $9.15 — trading 3.1% below its estimated fair value. The current ROE % is 7.01%, which is 184% above median its 10-year median of 2.47 and 189.7% above the Medical Devices & Instruments industry median of 2.42. InfuSystems Holdings' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current ROE % is 7.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be undervalued.
The current stock price of $9.15 is trading 3.1% below its estimated GF Value™ of $9.44.
GuruFocus considers InfuSystems Holdings to be Fairly Valued.
Key valuation signals for INFU:
ROE %: 7.01% (184% above median its 10-year median of 2.47)
GF Value™: $9.44 vs. price of $9.15 (3.1% below fair value)
Industry Position: 189.7% above the Medical Devices & Instruments median (#132 of 799)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
88GF Score
Get the complete analysis for INFU
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
